Shanghai Yuesai Biotechnology Co., Ltd. announced that it has received $31,500,000 in a round of funding co-led by ACME, LLC and CDH Investment Management Company Limited on March 14, 2022. The transaction also included participation from Kunlun Capital Pte Ltd, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Shanghai Guofang FOF Equity Investment Management Co., Ltd., Tibet RuiHua Capital Management Co., Ltd., returning investors TF Capital, GL Ventures.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.67 CNY | -0.17% | +2.07% | -5.43% |
04-30 | Fosun Pharma's Q1 Profit Slumps 38% | MT |
04-29 | Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.43% | 7.82B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- 600196 Stock
- News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Shanghai Yuesai Biotechnology Co., Ltd. announced that it has received $31.5 million in funding from a group of investors